Jefferies Maintains Buy Rating on Insulet Shares
Jefferies kept its Buy rating on Insulet while cutting the stock’s price target from $275.00 to $190.00 per share, Benzinga reports.
- published
- in the api
- on the website
on the website stories appear 15 minutes after publication, in the api at once. connect the api →
what happened
Jefferies maintained its Buy rating on Insulet shares but reduced the price target from $275.00 to $190.00 per share. Benzinga reported the action in its analyst-ratings data.
The information was published on October 12, 2026, at 18:37 GMT. Benzinga identifies Insulet by the ticker PODD in the report.
why it matters
The lower target alongside an unchanged Buy rating signals a revision to the analyst’s valuation while the overall stock recommendation remains intact. That distinction matters when markets assess Jefferies’ view of Insulet.
instruments
sources
- Insulet Is Maintained at Buy by Jefferies — Newsmetry API, 12 October 2026 at 18:37 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
on the website stories appear 15 minutes after publication, in the api at once.
get stories in real time ↗